BRCA2 and breast carcinoma: The ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) consortium has been playing an important role to evaluate the clinical significance of sequence variants in high-risk breast cancer genes including BRCA1 and BRCA2 genes since its establishment in 200913.